Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue

Vaccine

Volumn 28, Issue 51, 2010, Pages 8162-8168

  Keon, Soledad Mac ^a,b   Gazzaniga, Silvina ^a   Mallerman, Julieta ^a   Bravo, Alicia I ^c   Mordoh, José ^b   Wainstok, Rosa ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^c Hospital Eva Peron   (Argentina)

Author keywords

Apoptotic cell; Dendritic cell; Lymphoid tissue; Melanoma; Vaccination

Indexed keywords

ADDRESSIN; DENDRITIC CELL VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELL POPULATION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNITY; LYMPHOID TISSUE; MACROPHAGE; MALE; MELANOMA; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS LYMPHOID TISSUE; VACCINATION; VENULE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HISTOCYTOCHEMISTRY; INJECTIONS, SUBCUTANEOUS; LYMPHOID TISSUE; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SUBCUTANEOUS TISSUE; SURVIVAL ANALYSIS; VACCINATION;

EID: 78649663452     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.095     Document Type: Article

References (30)

1. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29(September (3)):372-383.
2. Palucka K., Ueno H., Fay J., Banchereau J. Harnessing dendritic cells to generate cancer vaccines. Ann N Y Acad Sci 2009, 1174(September):88-98.
3. Dillman R.O., Selvan S.R., Schiltz P.M., McClay E.F., Barth N.M., DePriest C., et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm 2009, 24(June (3)):311-319.
4. von Euw E.M., Barrio M.M., Furman D., Levy E.M., Bianchini M., Peguillet I., et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression. J Transl Med 2008, 6:6.
5. Steinman R.M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 2008, 29(September (3)):319-324.
6. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991, 9:271-296.
7. Martin-Fontecha A., Lanzavecchia A., Sallusto F. Dendritic cell migration to peripheral lymph nodes. Handb Exp Pharmacol 2009, 188:31-49.
8. Austyn J.M. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 1996, 183(April (4)):1287-1292.
9. Caux C., Vanbervliet B., Massacrier C., Ait-Yahia S., Vaure C., Chemin K., et al. Regulation of dendritic cell recruitment by chemokines. Transplantation 2002, 73(January (1 Suppl.)):S7-11.
10. Schrama D., Pedersen L.O., Keikavoussi P., Andersen M.H., Straten P.T.P., Brocker E.B., et al. Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells. J Invest Dermatol 2002, 119(December (6)):1443-1448.
11. Goldszmid R.S., Idoyaga J., Bravo A.I., Steinman R., Mordoh J., Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 2003, 171(December (11)):5940-5947.
12. Lappin M.B., Weiss J.M., Delattre V., Mai B., Dittmar H., Maier C., et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999, 98(October (2)):181-188.
13. MartIn-Fontecha A., Sebastiani S., Hopken U.E., Uguccioni M., Lipp M., Lanzavecchia A., et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003, 198(August (4)):615-621.
14. Eggert A.A., Schreurs M.W., Boerman O.C., Oyen W.J., de Boer A.J., Punt C.J., et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999, 59(July (14)):3340-3345.
15. Girard J.P., Springer T.A. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 1995, 16(September (9)):449-457.
16. Schrama D., Voigt H., Eggert A.O., Xiang R., Zhou H., Schumacher T.N., et al. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol Immunother 2008, 57(January (1)):85-95.
17. Irvine D.J., Stachowiak A.N., Hori Y. Lymphoid tissue engineering: invoking lymphoid tissue neogenesis in immunotherapy and models of immunity. Semin Immunol 2008, 20(April (2)):137-146.
18. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6(March (3)):205-217.
19. Nasr I.W., Reel M., Oberbarnscheidt M.H., Mounzer R.H., Baddoura F.K., Ruddle N.H., et al. Tertiary lymphoid tissues generate effector and memory T cells that lead to allograft rejection. Am J Transplant 2007, 7(May (5)):1071-1079.
20. Humby F., Bombardieri M., Manzo A., Kelly S., Blades M.C., Kirkham B., et al. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009, 6(January (1)):e1.
21. Thaunat O., Nicoletti A. Lymphoid neogenesis in chronic rejection. Curr Opin Organ Transplant 2008, 13(February (1)):16-19.
22. GeurtsvanKessel C.H., Willart M.A., Bergen I.M., van Rijt L.S., Muskens F., Elewaut D., et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med 2009, 206(October (11)):2339-2349.
23. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008, 26(September (27)):4410-4417.
24. Kirk C.J., Hartigan-O'Connor D., Mule J.J. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 2001, 61(December (24)):8794-8802.
25. Kalinski P., Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol 2010, (April).
26. Muthuswamy R., Urban J., Lee J.J., Reinhart T.A., Bartlett D., Kalinski P. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 2008, 68(July (14)):5972-5978.
27. Gustafsson K., Ingelsten M., Bergqvist L., Nystrom J., Andersson B., Karlsson-Parra A. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res 2008, 68(July (14)):5965-5971.
28. Lesterhuis W.J., Aarntzen E.H., De Vries I.J., Schuurhuis D.H., Figdor C.G., Adema G.J., et al. Dendritic cell vaccines in melanoma: from promise to proof?. Crit Rev Oncol Hematol 2008, 66(May (2)):118-134.
29. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5(April (4)):296-306.
30. Inzkirweli N., Guckel B., Sohn C., Wallwiener D., Bastert G., Lindner M. Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates. Anticancer Res 2007, 27(July-August (4B)):2121-2129.